Dihydroergotamine
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
midodrine
α1-selective adrenergic receptor agonist (prodrug) · Vasopressor
α1-selective adrenergic receptor agonist (prodrug)VasopressorATC C01CA17
CDSCO approvedATC C01CA17
EXCRETION
—
not curated
INTERACTIONS
6 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 6 →
- DihydroergotamineSevereDatabaseDDInter
- ErgometrineSevereDatabaseDDInter
- Ergotamine TartrateSevereDatabaseDDInter
- LinezolidSevereDatabaseDDInter
Mechanism
Midodrine is a prodrug, converted to desglymidodrine, which is a direct-acting α1 adrenergic receptor agonist. It causes rises in blood pressure by contracting both arterial and venous smooth muscle.
Indications
autonomic insufficiencypostural hypotension
Dosing
- Adult
- 2.5 to 10 mg three times daily (titrated)
- Max dose
- not specified, but careful titration
Pharmacokinetics
Peak effect
about 1 h (desglymidodrine)
Half-life
about 3 h (desglymidodrine)
Protein binding
duration of action about 4 to 6 h
Side effects
Serious
- supine hypertension
Drug interactions
Ergometrine
Severe
Database
Clinical effect not specified
Source: DDInter
Ergotamine Tartrate
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Linezolid
Severe
Database
Clinical effect not specified
Source: DDInter
Methylergometrine
Severe
Database
Clinical effect not specified
Source: DDInter
Methysergide
Severe
Database
Clinical effect not specified
Source: DDInter
6 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Related guidelines
Ask House about midodrine
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team